Zinc finger nuclease
Zinc-finger nucleases (ZFNs) are artificial restriction enzymes generated by fusing a zinc finger DNA-binding domain to a DNA-cleavage domain. Zinc finger domains can be engineered to target specific desired DNA sequences and this enables zinc-finger nucleases to target unique sequences within complex genomes. By taking advantage of endogenous DNA repair machinery, these reagents can be used to precisely alter the genomes of higher organisms. Alongside CRISPR/Cas9 and TALEN, ZFN is a prominent tool in the field of genome editing.
The DNA-binding domains of individual ZFNs typically contain between three and six individual zinc finger repeats and can each recognize between 9 and 18 basepairs. If the zinc finger domains perfectly recognize a 3 basepair DNA sequence, they can generate a 3-finger array that can recognize a 9 basepair target site. Other procedures can utilize either 1-finger or 2-finger modules to generate zinc-finger arrays with six or more individual zinc fingers. The main drawback with this procedure is the specificities of individual zinc fingers can overlap and can depend on the context of the surrounding zinc fingers and DNA. Without methods to account for this "context dependence", the standard modular assembly procedure often fails.
Numerous selection methods have been used to generate zinc-finger arrays capable of targeting desired sequences. Initial selection efforts utilized phage display to select proteins that bound a given DNA target from a large pool of partially randomized zinc-finger arrays. More recent efforts have utilized yeast one-hybrid systems, bacterial one-hybrid and two-hybrid systems, and mammalian cells. A promising new method to select novel zinc-finger arrays utilizes a bacterial two-hybrid system and has been dubbed "OPEN" by its creators. This system combines pre-selected pools of individual zinc fingers that were each selected to bind a given triplet and then utilizes a second round of selection to obtain 3-finger arrays capable of binding a desired 9-bp sequence. This system was developed by the Zinc-Finger Consortium as an alternative to commercial sources of engineered zinc-finger arrays.
(see: Zinc finger chimera for more info on zinc finger selection techniques)
The non-specific cleavage domain from the type IIs restriction endonuclease FokI is typically used as the cleavage domain in ZFNs. This cleavage domain must dimerize in order to cleave DNA and thus a pair of ZFNs are required to target non-palindromic DNA sites. Standard ZFNs fuse the cleavage domain to the C-terminus of each zinc finger domain. To let the two cleavage domains dimerize and cleave DNA, the two individual ZFNs must bind opposite strands of DNA with their C-termini a certain distance apart. The most commonly used linker sequences between the zinc finger domain and the cleavage domain requires the 5′ edge of each binding site to be separated by 5 to 7 bp.
Several different protein engineering techniques have been employed to improve both the activity and specificity of the nuclease domain used in ZFNs. Directed evolution has been employed to generate a FokI variant with enhanced cleavage activity that the authors dubbed "Sharkey". Structure-based design has also been employed to improve the cleavage specificity of FokI by modifying the dimerization interface so that only the intended heterodimeric species are active.
Zinc finger nucleases are useful to manipulate the genomes of many plants and animals including arabidopsis, tobacco, soybean, corn, Drosophila melanogaster, C. elegans, Platynereis dumerilii, sea urchin, silkworm, zebrafish, frogs, mice, rats, rabbits, pigs, cattle, and various types of mammalian cells. Zinc finger nucleases have also been used in a mouse model of haemophilia and a clinical trial found CD4+ human T-cells with the CCR5 gene disrupted by zinc finger nucleases to be safe as a potential treatment for HIV/AIDS. ZFNs are also used to create a new generation of genetic disease models called isogenic human disease models.
Disabling an allele
ZFNs can be used to disable dominant mutations in heterozygous individuals by producing double-strand breaks (DSBs) in the DNA (see Genetic recombination) in the mutant allele, which will, in the absence of a homologous template, be repaired by non-homologous end-joining (NHEJ). NHEJ repairs DSBs by joining the two ends together and usually produces no mutations, provided that the cut is clean and uncomplicated. In some instances, however, the repair is imperfect, resulting in deletion or insertion of base-pairs, producing frame-shift and preventing the production of the harmful protein. Multiple pairs of ZFNs can also be used to completely remove entire large segments of genomic sequence. To monitor the editing activity, a PCR of the target area amplifies both alleles and, if one contains an insertion, deletion, or mutation, it results in a heteroduplex single-strand bubble that cleavage assays can easily detect. ZFNs have also been used to modify disease-causing alleles in triplet repeat disorders. Expanded CAG/CTG repeat tracts are the genetic basis for more than a dozen inherited neurological disorders including Huntington's disease, myotonic dystrophy, and several spinocerebellar ataxias. It has been demonstrated in human cells that ZFNs can direct double-strand breaks (DSBs) to CAG repeats and shrink the repeat from long pathological lengths to short, less toxic lengths.
Recently, a group of researchers have successfully applied the ZFN technology to genetically modify the gol pigment gene and the ntl gene in zebrafish embryo. Specific zinc-finger motifs were engineered to recognize distinct DNA sequences. The ZFN-encoding mRNA was injected into one-cell embryos and a high percentage of animals carried the desired mutations and phenotypes. Their research work demonstrated that ZFNs can specifically and efficiently create heritable mutant alleles at loci of interest in the germ line, and ZFN-induced alleles can be propagated in subsequent generations.
Similar research of using ZFNs to create specific mutations in zebrafish embryo has also been carried out by other research groups. The kdr gene in zebra fish encodes for the vascular endothelial growth factor-2 receptor. Mutagenic lesions at this target site was induced using ZFN technique by a group of researchers in US. They suggested that the ZFN technique allows straightforward generation of a targeted allelic series of mutants; it does not rely on the existence of species-specific embryonic stem cell lines and is applicable to other vertebrates, especially those whose embryos are easily available; finally, it is also feasible to achieve targeted knock-ins in zebrafish, therefore it is possible to create human disease models that are heretofore inaccessible.
ZFNs are also used to rewrite the sequence of an allele by invoking the homologous recombination (HR) machinery to repair the DSB using the supplied DNA fragment as a template. The HR machinery searches for homology between the damaged chromosome and the extra-chromosomal fragment and copies the sequence of the fragment between the two broken ends of the chromosome, regardless of whether the fragment contains the original sequence. If the subject is homozygous for the target allele, the efficiency of the technique is reduced since the undamaged copy of the allele may be used as a template for repair instead of the supplied fragment.
The success of gene therapy depends on the efficient insertion of therapeutic genes at an appropriate chromosomal target site within the human genome, without causing cell injury, oncogenic mutations, or an immune response. The construction of plasmid vectors is simple and straightforward. Custom-designed ZFNs that combine the non-specific cleavage domain (N) of FokI endonuclease with zinc-finger proteins (ZFPs) offer a general way to deliver a site-specific DSB to the genome, and stimulate local homologous recombination by several orders of magnitude. This makes targeted gene correction or genome editing a viable option in human cells. Since ZFN-encoding plasmids could be used to transiently express ZFNs to target a DSB to a specific gene locus in human cells, they offer an excellent way for targeted delivery of the therapeutic genes to a pre-selected chromosomal site. The ZFN-encoding plasmid-based approach has the potential to circumvent all the problems associated with the viral delivery of therapeutic genes. The first therapeutic applications of ZFNs are likely to involve ex vivo therapy using a patients own stem cells. After editing the stem cell genome, the cells could be expanded in culture and reinserted into the patient to produce differentiated cells with corrected functions. Initial targets likely include the causes of monogenic diseases, such as the IL2Rγ gene and the β-globin gene for gene correction and CCR5 gene for mutagenesis and disablement.
If the zinc finger domains are not specific enough for their target site or they do not target a unique site within the genome of interest, off-target cleavage may occur. Such off-target cleavage may lead to the production of enough double-strand breaks to overwhelm the repair machinery and, as a consequence, yield chromosomal rearrangements and/or cell death. Off-target cleavage events may also promote random integration of donor DNA. Two separate methods have been demonstrated to decrease off-target cleavage for 3-finger ZFNs that target two adjacent 9-basepair sites. Other groups use ZFNs with 4, 5 or 6 zinc fingers that target longer and presumably rarer sites and such ZFNs could theoretically yield less off-target activity. A comparison of a pair of 3-finger ZFNs and a pair of 4-finger ZFNs detected off-target cleavage in human cells at 31 loci for the 3-finger ZFNs and at 9 loci for the 4-finger ZFNs. Whole genome sequencing of C. elegans modified with a pair of 5-finger ZFNs found only the intended modification and a deletion at a site "unrelated to the ZFN site" indicating this pair of ZFNs was capable of targeting a unique site in the C. elegans genome.
As with many foreign proteins inserted into the human body, there is a risk of an immunological response against the therapeutic agent and the cells in which it is active. Since the protein must be expressed only transiently, however, the time over which a response may develop is short.
Liu et al. respectively target ZFNickases to the endogenous b-casein(CSN2) locus stimulates lysostaphin and human lysozyme gene addition by homology-directed repair and derive secrete lysostaphin cows.
The ability to precisely manipulate the genomes of plants and animals has numerous applications in basic research, agriculture, and human therapeutics. Using ZFNs to modify endogenous genes has traditionally been a difficult task due mainly to the challenge of generating zinc finger domains that target the desired sequence with sufficient specificity. Improved methods of engineering zinc finger domains and the availability of ZFNs from a commercial supplier now put this technology in the hands of increasing numbers of researchers. Several groups are also developing other types of engineered nucleases including engineered homing endonucleases  and nucleases based on engineered TAL effectors. TAL effector nucleases (TALENs) are particularly interesting because TAL effectors appear to be very simple to engineer  and TALENs can be used to target endogenous loci in human cells. But to date no one has reported the isolation of clonal cell lines or transgenic organisms using such reagents. One type of ZFN, known as SB-728-T, has been tested for potential application in the treatment of HIV.
Zinc-finger nickases (ZFNickases) are created by inactivating the catalytic activity of one ZFN monomer in the ZFN dimer required for double-strand cleavage. ZFNickases demonstrate strand-specific nicking activity in vitro and thus provide for highly specific single-strand breaks in DNA. These SSBs undergo the same cellular mechanisms for DNA that ZFNs exploit, but they show a significantly reduced frequency of mutagenic NHEJ repairs at their target nicking site. This reduction provides a bias for HR-mediated gene modifications. ZFNickases can induce targeted HR in cultured human and livestock cells, although at lower levels than corresponding ZFNs from which they were derived because nicks can be repaired without genetic alteration. A major limitation of ZFN-mediated gene modifications is the competition between NHEJ and HR repair pathways. Regardless of the presence of a DNA donor construct, both repair mechanisms can be activated following DSBs induced by ZFNs. Thus, ZFNickases is the first plausible attempt at engineering a method to favor the HR method of DNA repair as opposed to the error-prone NHEJ repair. By reducing NHEJ repairs, ZFNickases can thereby reduce the spectrum of unwanted off-target alterations. The ease by which ZFNickases can be derive from ZFNs provides a great platform for further studies regarding the optimization of ZFNickases and possibly increasing their levels of targeted HR while still maintain their reduced NHEJ frequency.
- Chimeric nuclease
- Genome editing
- Gene targeting
- Zinc finger protein
- Zinc finger chimera
- Protein engineering
- Zinc finger nuclease treatment of HIV
- Ramirez CL, Foley JE, Wright DA, et al. (May 2008). "Unexpected failure rates for modular assembly of engineered zinc fingers". Nat. Methods. 5 (5): 374–375. doi:10.1038/nmeth0508-374. PMC 7880305. PMID 18446154.
- Maeder ML, et al. (September 2008). "Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification". Mol. Cell. 31 (2): 294–301. doi:10.1016/j.molcel.2008.06.016. PMC 2535758. PMID 18657511.
- Carroll D (2011). "Genome engineering with zinc-finger nucleases". Genetics. 188 (4): 773–782. doi:10.1534/genetics.111.131433. PMC 3176093. PMID 21828278.
- Kim YG, Cha J, Chandrasegaran S (1996). "Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain". Proc Natl Acad Sci USA. 93 (3): 1156–1160. Bibcode:1996PNAS...93.1156K. doi:10.1073/pnas.93.3.1156. PMC 40048. PMID 8577732.
- Bitinaite J, Wah, DA, Aggarwal AK, Schildkraut I (1998). "FokI dimerization is required for DNA cleavage". Proc Natl Acad Sci USA. 95 (18): 10570–10575. Bibcode:1998PNAS...9510570B. doi:10.1073/pnas.95.18.10570. PMC 27935. PMID 9724744.
- Cathomen T, Joung JK (July 2008). "Zinc-finger nucleases: the next generation emerges". Mol. Ther. 16 (7): 1200–1207. doi:10.1038/mt.2008.114. PMID 18545224.
- Guo J, Gaj T, Barbas CF (2010). "Directed Evolution of an Enhanced and Highly Efficient FokI Cleavage Domain for Zinc Finger Nucleases". Journal of Molecular Biology. 400 (1): 96–107. doi:10.1016/j.jmb.2010.04.060. PMC 2885538. PMID 20447404.
- Szczepek M, Brondani V, Büchel J, Serrano L, Segal DJ, Cathomen T (2007). "Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases". Nature Biotechnology. 25 (7): 786–793. doi:10.1038/nbt1317. PMID 17603476. S2CID 22079561.
- Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, Rupniewski I, Beausejour CM, Waite AJ, Wang NS, Kim KA, Gregory PD, Pabo CO, Rebar EJ (2007). "An improved zinc-finger nuclease architecture for highly specific genome editing". Nature Biotechnology. 25 (7): 778–785. doi:10.1038/nbt1319. PMID 17603475. S2CID 205273515.
- Doyon Y, Vo TD, Mendel MC, Greenberg SG, Wang J, Xia DF, Miller JC, Urnov FD, Gregory PD, Holmes MC (2010). "Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures". Nature Methods. 8 (1): 74–79. doi:10.1038/nmeth.1539. PMID 21131970. S2CID 14334237.
- Ramalingam S, Kandavelou K, Rajenderan R, Chandrasegaran S (2011). "Creating Designed Zinc-Finger Nucleases with Minimal Cytotoxicity". Journal of Molecular Biology. 405 (3): 630–641. doi:10.1016/j.jmb.2010.10.043. PMC 3017627. PMID 21094162.
- Zhang F, Maeder ML, Unger-Wallace E, Hoshaw JP, Reyon D, Christian M, Li X, Pierick CJ, Dobbs D, Peterson T, Joung JK, Voytas DF (2010). "High frequency targeted mutagenesis in Arabidopsis thaliana using zinc finger nucleases". Proceedings of the National Academy of Sciences. 107 (26): 12028–12033. Bibcode:2010PNAS..10712028Z. doi:10.1073/pnas.0914991107. PMC 2900673. PMID 20508152.
- Osakabe K, Osakabe Y, Toki S (2010). "Site-directed mutagenesis in Arabidopsis using custom-designed zinc finger nucleases". Proceedings of the National Academy of Sciences. 107 (26): 12034–12039. Bibcode:2010PNAS..10712034O. doi:10.1073/pnas.1000234107. PMC 2900650. PMID 20508151.
- Cai CQ, Doyon Y, Ainley WM, Miller JC, Dekelver RC, Moehle EA, Rock JM, Lee YL, Garrison R, Schulenberg L, Blue R, Worden A, Baker L, Faraji F, Zhang L, Holmes MC, Rebar EJ, Collingwood TN, Rubin-Wilson B, Gregory PD, Urnov FD, Petolino JF (2008). "Targeted transgene integration in plant cells using designed zinc finger nucleases". Plant Molecular Biology. 69 (6): 699–709. doi:10.1007/s11103-008-9449-7. ISSN 0167-4412. PMID 19112554. S2CID 6826269.
- Townsend JA, Wright DA, Winfrey RJ, Fu F, Maeder ML, Joung JK, Voytas DF (2009). "High-frequency modification of plant genes using engineered zinc-finger nucleases". Nature. 459 (7245): 442–445. Bibcode:2009Natur.459..442T. doi:10.1038/nature07845. PMC 2743854. PMID 19404258.
- Curtin SJ, Zhang F, Sander JD, Haun WJ, Starker C, Baltes NJ, Reyon D, Dahlborg EJ, Goodwin MJ, Coffman AP, Dobbs D, Joung JK, Voytas DF, Stupar RM (2011). "Targeted Mutagenesis of Duplicated Genes in Soybean with Zinc-Finger Nucleases". Plant Physiology. 156 (2): 466–473. doi:10.1104/pp.111.172981. PMC 3177250. PMID 21464476.
- Shukla VK, Doyon Y, Miller JC, et al. (May 2009). "Precise genome modification in the crop species Zea mays using zinc-finger nucleases". Nature. 459 (7245): 437–441. Bibcode:2009Natur.459..437S. doi:10.1038/nature07992. PMID 19404259. S2CID 4323298.
- Bibikova M, Beumer K, Trautman J, Carroll D (2003). "Enhancing Gene Targeting with Designed Zinc Finger Nucleases". Science. 300 (5620): 764. doi:10.1126/science.1079512. PMID 12730594. S2CID 42087531.
- Wood AJ, Lo TW, Zeitler B, Pickle CS, Ralston EJ, Lee AH, Amora R, Miller JC, Leung E, Meng X, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Meyer BJ (2011). "Targeted Genome Editing Across Species Using ZFNs and TALENs". Science. 333 (6040): 307. Bibcode:2011Sci...333..307W. doi:10.1126/science.1207773. PMC 3489282. PMID 21700836.
- Gühmann M, Jia H, Randel N, Verasztó C, Bezares-Calderón LA, Michiels NK, Yokoyama S, Jékely G (August 2015). "Spectral Tuning of Phototaxis by a Go-Opsin in the Rhabdomeric Eyes of Platynereis". Current Biology. 25 (17): 2265–2271. doi:10.1016/j.cub.2015.07.017. PMID 26255845.
- Ochiai H, Fujita K, Suzuki KI, Nishikawa M, Shibata T, Sakamoto N, Yamamoto T (2010). "Targeted mutagenesis in the sea urchin embryo using zinc-finger nucleases". Genes to Cells. 15 (8): 875–885. doi:10.1111/j.1365-2443.2010.01425.x. PMID 20604805.
- Takasu Y, Kobayashi I, Beumer K, Uchino K, Sezutsu H, Sajwan S, Carroll D, Tamura T, Zurovec M (2010). "Targeted mutagenesis in the silkworm Bombyx mori using zinc finger nuclease mRNA injection". Insect Biochemistry and Molecular Biology. 40 (10): 759–765. doi:10.1016/j.ibmb.2010.07.012. PMID 20692340.
- Ekker SC (2008). "Zinc Finger–Based Knockout Punches for Zebrafish Genes". Zebrafish. 5 (2): 1121–1123. doi:10.1089/zeb.2008.9988. PMC 2849655. PMID 18554175.
- Young JJ, Cherone JM, Doyon Y, Ankoudinova I, Faraji FM, Lee AH, Ngo C, Guschin DY, Paschon DE, Miller JC, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Harland RM, Zeitler B (2011). "Efficient targeted gene disruption in the soma and germ line of the frog Xenopus tropicalis using engineered zinc-finger nucleases". Proceedings of the National Academy of Sciences. 108 (17): 7052–7057. Bibcode:2011PNAS..108.7052Y. doi:10.1073/pnas.1102030108. PMC 3084115. PMID 21471457.
- Goldberg AD, Banaszynski LA, Noh KM, Lewis PW, Elsaesser SJ, Stadler S, Dewell S, Law M, Guo X, Li X, Wen D, Chapgier A, Dekelver RC, Miller JC, Lee YL, Boydston EA, Holmes MC, Gregory PD, Greally JM, Rafii S, Yang C, Scambler PJ, Garrick D, Gibbons RJ, Higgs DR, Cristea IM, Urnov FD, Zheng D, Allis CD (2010). "Distinct Factors Control Histone Variant H3.3 Localization at Specific Genomic Regions". Cell. 140 (5): 678–691. doi:10.1016/j.cell.2010.01.003. PMC 2885838. PMID 20211137.
- Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, Choi VM, Jenkins SS, Wood A, Cui X, Meng X, Vincent A, Lam S, Michalkiewicz M, Schilling R, Foeckler J, Kalloway S, Weiler H, Menoret S, Anegon I, Davis GD, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Jacob HJ, Buelow R (2009). "Knockout Rats via Embryo Microinjection of Zinc-Finger Nucleases". Science. 325 (5939): 433. Bibcode:2009Sci...325..433G. doi:10.1126/science.1172447. PMC 2831805. PMID 19628861.
- Flisikowska T, Thorey IS, Offner S, Ros F, Lifke V, Zeitler B, Rottmann O, Vincent A, Zhang L, Jenkins S, Niersbach H, Kind AJ, Gregory PD, Schnieke AE, Platzer J (2011). Milstone DS (ed.). "Efficient Immunoglobulin Gene Disruption and Targeted Replacement in Rabbit Using Zinc Finger Nucleases". PLOS ONE. 6 (6): e21045. Bibcode:2011PLoSO...621045F. doi:10.1371/journal.pone.0021045. PMC 3113902. PMID 21695153.
- Hauschild J, Petersen B, Santiago Y, Queisser AL, Carnwath JW, Lucas-Hahn A, Zhang L, Meng X, Gregory PD, Schwinzer R, Cost GJ, Niemann H (2011). "Efficient generation of a biallelic knockout in pigs using zinc-finger nucleases". Proceedings of the National Academy of Sciences. 108 (29): 12013–12017. Bibcode:2011PNAS..10812013H. doi:10.1073/pnas.1106422108. PMC 3141985. PMID 21730124.
- Yu S, Luo J, Song Z, Ding F, Dai Y, Li N (2011). "Highly efficient modification of beta-lactoglobulin (BLG) gene via zinc-finger nucleases in cattle". Cell Research. 21 (11): 1638–1640. doi:10.1038/cr.2011.153. PMC 3364726. PMID 21912434.
- Carroll D (2008). "Zinc-finger Nucleases as Gene Therapy Agents". Gene Therapy. 15 (22): 1463–1468. doi:10.1038/gt.2008.145. PMC 2747807. PMID 18784746.
- Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS, Malani N, Anguela XM, Sharma R, Ivanciu L, Murphy SL, Finn JD, Khazi FR, Zhou S, Paschon DE, Rebar EJ, Bushman FD, Gregory PD, Holmes MC, High KA (2011). "In vivo genome editing restores haemostasis in a mouse model of haemophilia". Nature. 475 (7355): 217–221. doi:10.1038/nature10177. PMC 3152293. PMID 21706032.
- Tebas P, Stein D, Tang WV, Frank I, Wang S, Lee G, Spratt SK, Surosky RT, Giedlin M, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang WT, Levine B, June CH (6 March 2014). "Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV". New England Journal of Medicine. 370 (10): 901–910. doi:10.1056/NEJMoa1300662. PMC 4084652. PMID 24597865.
- Durai S, Mani M, Kandavelou K, Wu J, Porteus MH, Chandrasegaran S (2005). "Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells". Nucleic Acids Res. 33 (18): 5978–5990. doi:10.1093/nar/gki912. PMC 1270952. PMID 16251401.
- Lee HJ, Kim E, Kim JS (December 2009). "Targeted chromosomal deletions in human cells using zinc finger nucleases". Genome Res. 20 (1): 81–89. doi:10.1101/gr.099747.109. PMC 2798833. PMID 19952142.
- Mittelman D, Moye C, Morton J, Sykoudis K, Lin Y, Carroll D, Wilson JH (16 June 2009). "Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells". Proceedings of the National Academy of Sciences of the United States of America. 106 (24): 9607–9612. Bibcode:2009PNAS..106.9607M. doi:10.1073/pnas.0902420106. PMC 2701052. PMID 19482946.
- Kandavelou K, Chandrasegaran S (2008). "Plasmids for Gene Therapy". Plasmids: Current Research and Future Trends. Norfolk: Caister Academic Press. ISBN 978-1-904455-35-6.
- Gupta A, Meng X, Zhu LJ, Lawson ND, Wolfe SA (September 2010). "Zinc finger protein-dependent and -independent contributions to the in vivo off-target activity of zinc finger nucleases". Nucleic Acids Res. 39 (1): 381–392. doi:10.1093/nar/gkq787. PMC 3017618. PMID 20843781.
- Pattanayak V, Ramirez CL, Joung JK, Liu DR (2011). "Revealing Off-Target Cleavage Specificities of Zinc Finger Nucleases by in Vitro Selection". Nature Methods. 8 (9): 765–770. doi:10.1038/nmeth.1670. PMC 3164905. PMID 21822273.
- Liu X, Wang YS, Guo WJ, Chang BH, Liu J, Guo ZK, Quan FS, Zhang Y (2013). "Zinc-finger nickase-mediated insertion of the lysostaphin gene into the beta-casein locus in cloned cows". Nature Communications. 4: 2565. Bibcode:2013NatCo...4.2565L. doi:10.1038/ncomms3565. PMC 3826644. PMID 24121612.
- Liu X, Wang Y, Tian Y, Yu Y, Gao M, Hu G, Su F, Pan S, Luo Y, Guo Z, Quan F, Zhang Y (2014). "Generation of mastitis resistance in cows by targeting human lysozyme gene to -casein locus using zinc-finger nucleases". Proceedings of the Royal Society B: Biological Sciences. 281 (1780): 20133368. doi:10.1098/rspb.2013.3368. PMC 4027401. PMID 24552841.
- Grizot S, Smith J, Daboussi F, et al. (September 2009). "Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease". Nucleic Acids Res. 37 (16): 5405–5419. doi:10.1093/nar/gkp548. PMC 2760784. PMID 19584299.
- Gao H, Smith J, Yang M, Jones S, Djukanovic V, Nicholson MG, West A, Bidney D, Falco SC, Jantz D, Lyznik LA (2010). "Heritable targeted mutagenesis in maize using a designed endonuclease". The Plant Journal. 61 (1): 176–187. doi:10.1111/j.1365-313X.2009.04041.x. PMID 19811621.
- Christian M, Cermak T, Doyle EL, et al. (July 2010). "Targeting DNA Double-Strand Breaks with TAL Effector Nucleases". Genetics. 186 (2): 757–761. doi:10.1534/genetics.110.120717. PMC 2942870. PMID 20660643.
- Li T, Huang S, Jiang WZ, et al. (August 2010). "TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain". Nucleic Acids Res. 39 (1): 359–372. doi:10.1093/nar/gkq704. PMC 3017587. PMID 20699274.
- Moscou MJ, Bogdanove AJ (December 2009). "A simple cipher governs DNA recognition by TAL effectors". Science. 326 (5959): 1501. Bibcode:2009Sci...326.1501M. doi:10.1126/science.1178817. PMID 19933106. S2CID 6648530.
- Boch J, Scholze H, Schornack S, Hahn S, Kay S, Lahaye T, Nickstadt A, Bonas U (December 2009). "Breaking the code of DNA binding specificity of TAL-type III effectors". Science. 326 (5959): 1509–1512. Bibcode:2009Sci...326.1509B. doi:10.1126/science.1178811. PMID 19933107. S2CID 206522347.
- Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ, Dulay GP, Hua KL, Ankoudinova I, Cost GJ, Urnov FD, Zhang HS, Holmes MC, Zhang L, Gregory PD, Rebar EJ (2010). "A TALE nuclease architecture for efficient genome editing". Nature Biotechnology. 29 (2): 143–148. doi:10.1038/nbt.1755. PMID 21179091. S2CID 53549397.
- Wade N (28 December 2009). "Zinc Fingers Could Be Key to Reviving Gene Therapy". The New York Times. Retrieved 31 May 2016.
- Ramirez CL, Certo MT, Mussolino C, Goodwin MJ, Cradick TJ, McCaffrey AP, Cathomen T, Scharenberg AM, Joung JK (2012). "Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects". Nucleic Acids Research. 40 (7): 5560–5568. doi:10.1093/nar/gks179. PMC 3384306. PMID 22373919.
- Wang J, Friedman G, Doyon Y, Wang NS, Li CJ, Miller JC, Hua KL, Yan JE, Babiarz PD, Gregory PD, Holmes MC (2012). "Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme". Genome Research. 22 (4): 1316–1326. doi:10.1101/gr.122879.111. PMC 3396372. PMID 22434427.
- Mandell JG, Barbas CF (July 2006). "Zinc Finger Tools: custom DNA-binding domains for transcription factors and nucleases". Nucleic Acids Res. 34 (Web Server issue): W516–23. doi:10.1093/nar/gkl209. PMC 1538883. PMID 16845061.
- Porteus MH, Carroll D (August 2005). "Gene targeting using zinc finger nucleases". Nat. Biotechnol. 23 (8): 967–973. doi:10.1038/nbt1125. PMID 16082368. S2CID 13221399.
- Doyon Y, McCammon JM, Miller JC, et al. (June 2008). "Heritable Targeted Gene Disruption in Zebrafish Using Designed Zinc Finger Nucleases". Nat. Biotechnol. 26 (6): 702–708. doi:10.1038/nbt1409. PMC 2674762. PMID 18500334.
- Meng X, Noyes MB, Zhu LJ, Lawson ND, Wolfe SA (June 2008). "Targeted gene inactivation in zebrafish using engineered zinc finger nucleases". Nat. Biotechnol. 26 (6): 695–701. doi:10.1038/nbt1398. PMC 2502069. PMID 18500337.